| CLYM |
Climb Bio, Inc. |
72%
|
Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM g… |
| CLYM |
Climb Bio, Inc. |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subs… |
| NVSEF |
Novartis AG |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| ORKA |
Oruka Therapeutics, Inc. |
72%
|
Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA g… |
| ORKA |
Oruka Therapeutics, Inc. |
72%
|
are negotiating agreements with the federal government regarding most favored nation pricing and onshoring of production and research and development. Any direct tariffs, if imposed on pharmaceutical… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from JBIO graph: property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be … |
| SNYNF |
Sanofi |
72%
|
property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. Further, we may be required to protect our future patents, i… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subs… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarte… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA g… |
| VOR |
Vor Biopharma Inc. |
72%
|
Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR grap… |
| VOR |
Vor Biopharma Inc. |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our existing and future product candidates thr… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase subst… |
| AEROVATE-THERAPEUTICS-INC |
AEROVATE-THERAPEUTICS-INC |
62%
|
e three months ended March 31, 2026. As of March 31, 2026, we had an accumulated deficit of $214.8 million. For the three months ended March 31, 2026, we used net cash of $24.1 million for our operat… |
| AEROVATE-THERAPEUTICS-INC-CARIBBEAN-MERGER-SUB-I |
AEROVATE-THERAPEUTICS-INC-CARIBBEAN-MERGER-SUB-I |
62%
|
are negotiating agreements with the federal government regarding most favored nation pricing and onshoring of production and research and development. Any direct tariffs, if imposed on pharmaceutical… |
| CARIBBEAN-MERGER-SUB-II-LLC |
CARIBBEAN-MERGER-SUB-II-LLC |
62%
|
are negotiating agreements with the federal government regarding most favored nation pricing and onshoring of production and research and development. Any direct tariffs, if imposed on pharmaceutical… |
| CARIBBEAN-MERGER-SUB-I-INC |
CARIBBEAN-MERGER-SUB-I-INC |
62%
|
e three months ended March 31, 2026. As of March 31, 2026, we had an accumulated deficit of $214.8 million. For the three months ended March 31, 2026, we used net cash of $24.1 million for our operat… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
r expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market. Risks associated with the in… |
| JADE-BIOSCIENCES-LLC |
JADE-BIOSCIENCES-LLC |
62%
|
e three months ended March 31, 2026. As of March 31, 2026, we had an accumulated deficit of $214.8 million. For the three months ended March 31, 2026, we used net cash of $24.1 million for our operat… |
| PARADE-BIOSCIENCES-HOLDING-LLC |
PARADE-BIOSCIENCES-HOLDING-LLC |
62%
|
then-outstanding option to purchase Pre-Merger Jade common stock was assumed by Aerovate and was converted into an option to purchase shares of Company common stock, subject to adjustment as set fort… |
| PARAGON-THERAPEUTICS-INC |
PARAGON-THERAPEUTICS-INC |
62%
|
are negotiating agreements with the federal government regarding most favored nation pricing and onshoring of production and research and development. Any direct tariffs, if imposed on pharmaceutical… |
| SUBSEQUENTLY-JADE-BIOSCIENCES-LLC |
SUBSEQUENTLY-JADE-BIOSCIENCES-LLC |
62%
|
e three months ended March 31, 2026. As of March 31, 2026, we had an accumulated deficit of $214.8 million. For the three months ended March 31, 2026, we used net cash of $24.1 million for our operat… |
